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Abstract 
We report the detailed long-term reconstitu-
tion of B-lymphocyte subpopulations, immuno -
globulins, and specific antibody production after
two courses of rituximab in a young, previously
healthy girl with steroid-dependent autoim-
mune hemolytic anemia. B-lymphocyte subpop-
ulations were surprisingly normal directly after
reconstitution. However, there was a slower
reconstitution after the second rituximab
course, especially of non-switched and switched
memory B-lymphocytes, and a temporary decline
in IgM below age-matched reference values.
Introduction
Rituximab is increasingly used in the treat-
ment of various hematological malignancies
and, more recently, autoimmune diseases like
autoimmune hemolytic anemia (AIHA).1
Rituximab is a monoclonal antibody that reacts
with the CD20 antigen, which is expressed on
pre-B and mature B-lymphocytes, but not on
plasma cells. B-lymphocytes play an important
regulatory and potentially pathogenic role in
autoimmune diseases through antibody-inde-
pendent mechanisms like antigen presenta-
tion, T-lymphocyte activation, and the produc-
tion of cytokines and chemokines.2,3 They are
also the precursors of (auto)antibody-produc-
ing plasma cells. Depletion of B-lymphocytes is
therefore likely to interfere with the complex
(auto)immune process, but the exact mecha-
nism of its effect on autoimmune diseases is
not yet fully understood.4
Treatment with rituximab results in a rapid
and sustained depletion of B-lymphocytes.
There are detailed reports on the rate and phe-
notype of B-lymphocyte subpopulation recovery
after rituximab treatment in adults:5-12 after B-
cell depletion immature B-lymphocytes reap-
pear first, followed by naïve B-lymphocytes;
CD27+ memory B-lymphocytes may remain
reduced up to 2 years after rituximab treat-
ment.5,8
It would be expected that depletion of CD20+
B-lymphocytes has direct effects on antibody
production, and indirect effects on cellular
immunity. Indeed, hypogammaglobulinemia
requiring substitution was recently described
in a child with repeated rituximab treatment
for idiopathic thrombocytopenic purpura and
underlying autoimmune lymphoproliferative
disease.13 However, until now large numbers of
serious infectious complications of rituximab
treatment have not been described,4 perhaps
because antibody-producing plasma cells are
spared.
In this paper, we give a detailed description
of the reconstitution of B-lymphocyte subpopu-
lations, immunoglobulins (Igs), and specific
antibody production after repeated treatment
with rituximab in a young, previously healthy,
girl with steroid-dependent AIHA.
Materials and MethodsPatient
In August 2004, a previously healthy 13-
months-old girl presented in our hospital with
AIHA which turned out to be steroid-depend-
ent. Aspecific IgG autoantibodies were strong-
ly positive. In August 2005, she was treated
with rituximab (4¥375 mg/m2, 1 week apart).
Human anti-chimeric antibodies (HACAs)
were measured once and found negative.
Subsequently, steroids could be tapered and
stopped 11 months after the first rituximab
treatment, in July 2006. A few weeks later, she
suffered a relapse and steroids were restarted,
and a second course with 4 gifts of rituximab
(375 mg/m2, 1 week apart) was administered.
Hereafter, the steroid dose was slowly reduced
again, and 11 months after the second treat-
ment with rituximab, in July 2007, at the age of
4 years, steroids were stopped completely. In
2011, at almost 8 years of age, there were still
no signs of relapse. Aspecific IgG autoantibod-
ies remained negative. She did not suffer from
any significant infections. The clinical course
of this girl is illustrated in Figure 1.
Preceding rituximab treatment, but while
on steroids, vaccination status was optimised
using Prevenar twice (Wyeth) followed by
Pneumovax (Sanofi Pasteur MSD) for S. pneu-
moniae, and NeisVacC (Baxter) and
MeningovaxAC (Sanofi Pasteur MSD) for S.
meningitidis. This was considered important,
because both rituximab and prolonged steroid
treatment might compromise immunity. After
2.5 years, Pneumovax and Mencevax ACWY
(Glaxo Smith Kline) vaccinations were given.
Diphtheria - tetanus - inactivated poliomyelitis
(DTP-NVI) vaccination was given at the age of
four, according to the regular Dutch immuni-
sation schedule (Figure 1).
Peripheral blood samples were taken at mul-
tiple time points (t = 0, 8, 14, 21, 56, 110, 202,
321, 383, 396, 403, 410, 417, 446, 530, 614, 718,
816, 1085 days after the first rituximab dose,
indicated with arrows in Figure 1) to establish
the reconstitution of B-lymphocyte subpopula-
tions, Ig titers and specific antibody production.Immunophenotyping
Four-color flow cytometric immunopheno-
typing was performed using the lyse and wash
whole-blood method. Aliquots of ethylene di-
aminetetra-acetic (EDTA) blood (50 μL) were
incubated for 15 min at room temperature in
the dark with the following monoclonal anti-
bodies: isotype control gamma 1 conjugated to
fluorescein isothiocyanate (FITC) (Becton
Dickinson, San Jose, CA, USA (BD)), isotype
control gamma 2a conjugated to phycoerythrin
(PE) (BD), CD3-FITC (Immuno Quality
Products, Groningen, The Netherlands (IQP)),
CD3 conjugated to allophycocyanin (APC)
(BD), CD3 conjugated to PE-Cyanin5 (PE-Cy5)
(Coulter Immunotech, Marseille, France (CI)),
CD4-PE (IQP), CD4-PE-Cy5 (CI), CD5-FITC
(BD), CD8-PE (IQP), CD8 conjugated to peri-
dinin chlorophyll protein cyanin 5.5 (PerCP-
Cy5.5) (BD), CD10-APC (BD), CD16/56-PE
(BD), CD19-PE (BD), CD19-PE-Cy5 (CI),
CD19-PerCP-Cy5.5 (BD), CD20-FITC (BD),
CD21-PE (BD), CD25-FITC (CI), CD27-FITC
(BD), CD27-PE (BD), CD45RA-PE (CI),
CD45RO-FITC (BD or IQP), IgD-FITC
(SouthernBiotech, Birmingham, USA), and
IgM-FITC (Sanofi Pasteur Marnes-La-
Coquette, France). To eliminate immunoglobu-
lins, aliquots destined for anti-IgM and anti-
IgD were washed three times before staining.
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Erythrocytes were lysed using FACSLysing
solution (BD) according to the manufacturer’s
protocol. The cells were washed twice with
0.5% bovine serum albumin/phosphate-
buffered saline. Analysis was performed using
CellQuest ProSoftware (BD) on a FACSCalibur
flowcytometer (BD), which was calibrated
according to the guidelines of Kraan et al.14
The absolute leukocyte count (¥109/L) was
determined on a Sysmex XE-2100 hematology
analyzer (Sysmex, Kobe, Japan). The absolute
number (¥109/L) of a lymphocyte subpopula-
tion was calculated by multiplying the calculat-
ed absolute lymphocyte size (¥109/L) with the
relative size of the lymphocyte subpopulation
(%) within the lymphocyte gate. The values
were compared to reference values in healthy
children derived from our laboratory.Immunoglobulins
IgG, IgA, IgM, and IgG-subclasses were
determined by standard nephelometric meth-
ods (BNProspec, Dade Behring, The
Netherlands). Specific antibody responses to
pneumococcal vaccination were determined by
ELISA, diphtheria and tetanus antitoxin anti-
bodies with a toxin-binding inhibition
assay.15,16
Results
As expected, all peripheral blood B-lympho-
cyte subpopulations disappeared rapidly upon
treatment with rituximab (Figure 2), T-lym-
phocyte subpopulation and NK-cell counts
were not affected (Table 1). After the first rit-
uximab course, B-cells reappeared at t = 110
days, after the second course they reappeared
later, at t = 614 (218 days after the second rit-
uximab course). The reappearing cells were
mainly naive cells (CD19+IgD+CD27-), around
one third were CD5+ (Figure 2). After the sec-
ond course, both non-switched
(CD19+IgD+CD27+) and switched (CD19+IgD-
CD27+) memory B-lymphocytes reappeared
later than after the first course (at t = 110 days
after the first course, together with the naive
cells, and at 320 days after the second course,
which is 102 days after the first naive cells, at
t = 718 days (Figure 2). However, switched
memory B-lymphocytes were within the age-
limits of normal from the moment they reap-
peared (Table 1). CD21+ cells (IgM- and IgM+)
repopulated in the same manner as the other
B-lymphocyte subpopulations.
IgG, IgA, and IgG-subclass levels were unaf-
fected by the rituximab treatment (Table 1),
but after the second course a temporary
decrease in IgM was found (0.48 g/l at t = 446
days; 0.23 g/l at t = 530 days; 0,6 g/l at t = 614
days), as has been described before.17,18 After
both rituximab treatments prednisone was
used every other day and slowly tapered until it
could be stopped. After the first treatment with
rituximab the dosage of prednisone was slight-
ly higher. During that time we didn’t see an
effect on immunoglobulins or significant
infections. Vaccination responses before the
first rituximab course were normal; booster
responses after the second course (after t =
1085 days) were normal as well (Table 1),
despite the fact that she had been on steroids
during the first round of vaccinations.
Discussion
We followed a girl with steroid-dependent
AIHA who was treated with 4 gifts of rituximab
twice. She repopulated mainly with naive B-
lymphocytes, around one third CD5+, as could
be expected for her age. Interestingly, her B-
lymphocytes returned to normal faster than
described before in both adults5-7 and chil-
dren,17,18 but these children had underlying
diseases that may have influenced the recon-
stitution. She did not suffer any significant
infections, and responded well to vaccination,
despite her prolonged steroid use.
During repopulation memory B-lymphocytes
peaked just before the relapse in our patient.
Increasingly, early relapse of autoimmune dis-
eases like rheumatoid arthritis or SLE are
reported in adult patients with a higher num-
ber of memory B-lymphocytes in early reconsti-
tution in comparison to patients with later or
no relapse.5,8,10 Our case suggests that this
relation may also exist in children.
After the second rituximab treatment, the
reconstitution was somewhat slower in our
patient. This has been described by others,4,13
suggesting that multiple rituximab courses
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Table 1. Absolute values of lymphocyte subpopulations in comparison with control values from healthy age-matched children.
time in days t=0 t=110 t=396 t=614 t=718
CD19+ 0.86* 0.34 0.54 0.33 0.54
total B-lymphocytes 0.76 (0.3-2.8)** 0.76 (0.3-2.8) 0.49 (0.3-0.7) 0.49 (0.3-0.7) 0.49 (0.3-0.7)
CD19+CD5+ 0.54 0.14 0.08 0.038 0.16
CD5+ B-lymphocytes 0.39 (0.1-1.3) 0.39 (0.1-1.3) 0.15 (0.0-0.4) 0.15 (0.0-0.4) 0.15 (0.0-0.4)
CD19+CD10+ 0.18 0.07 0.48 0.33 0.13
Immature B-lymphocytes 0.24 (0.09-0.87) 0.24 (0.09-0.87) 0.12 (0.04-0.25) 0.12 (0.04-0.25) 0.12 (0.04-0.25)
CD19+IgD+CD27- 0.74 0.28 0.36 0.30 0.47
naive B-lymphocytes 0.61 (0.24-2.61) 0.61 (0.24-2.61) 0.37 (0.20-0.59) 0.37 (0.20-0.59) 0.37 (0.20-0.59)
CD19+IgD+CD27+ 0.06 0.01 0.08 0.013 0.027
non-switched memory
B-lymphocytes 0.04 (0.01-0.12) 0.04 (0.01-0.12) 0.04 (0.02-0.1) 0.04 (0.02-0.1) 0.04 (0.02-0.1)
CD19+IgD-CD27+ 0.05 0.04 0.072 0.086 0.032
switched memory
B-lymphocytes 0.022 (0.005-0.03) 0.022 (0.005-0.03) 0.040 (0.012-0.13) 0.040 (0.012-0.13) 0.040 (0.012-0.13)
CD3+ cells 2.79 2.64 1.11 2.58 2.12
(T lymphocytes) 2.5 (0.7-8.8) 1.9 (0.85-4.3) 1.9 (0.85-4.3) 1.9 (0.85-4.3)
NK cells 0.28 0.18 0.44 0.32 0.24
0.47 (0.055-4.0) 0.18 (0.061-0.51) 0.18 (0.061-0.51) 0.18 (0.061-0.51)
IgG*** 5.8 6.2 8.6 5.9 7.2
IgA*** 0.52 0.68 0.92 0.88 1.23
IgM*** 1.07 0.65 1.56 0.6 0,54
*Value in patient in 109/l. **Median (range) of healthy age-matched controls in 109/l. t = 0: start of first rituximab course; t = 396: start of second rituximab course; t=614: start of recovery after second rituximab course;
t = 718: full recovery of all B-lymphocyte subpopulations. ***Immunoglobulins in g/L.
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may eventually lead to secondary antibody defi-
ciency and infectious complications. Future
studies in larger numbers of children are need-
ed to analyze this further. 
References
1. Quartier P, Brethon B, Philippet P, et al.
Treatment of childhood autoimmune
haemolytic anaemia with rituximab.
Lancet 2001;358:1511-13.
2. Kessel A, Rosner I, Toubi E. Rituximab:
beyond simple B cell depletion. Clinic Rev
Allergy Immunol 2008;34:74-9.
3. Stamatis-Nick CL, Sfikakis PP. Rituximab-
induced B cell depletion in autoimmune
diseases: Potential effects on T cells. Clin
Imm 2008;127:280-5.
4. Cooper N, Arnold DM. The effect of ritux-
imab on humoral and cell mediated immu-
nity and infection in the treatment of
autoimmune diseases. B J Haematol
2010;149:3-13.
5. Leandro MJ, Cambridge G, Ehrenstein MR,
Edwars JC. Reconstitution of peripheral
blood B cells after depletion with ritux-
imab in patients with rheumatoid arthri-
tis. Arthritis Rheum 2006;54:613-20.
6. Roll P, Palanichamy A, Kneitz C, et al.
Regeneration of B cell subsets after tran-
sient B cell depletion using anti-CD20
antibodies in rheumatoid arthritis.
Arthritis Rheum 2006;54:2377-86.
7. Sidner RA, Book BK, Agarwal A, et al. In
vivo human B-cell subset recovery after in
vivo depletion with rituximab, anti-human
CD20 monoclonal antibody. Human
Antibodies 2004;13:55-62.
8. Roll P, Dörner T, Tony, HP. Anti-CD20 ther-
apy in patients with rheumatoid arthritis.
Predictors of response and B cell subset
regeneration after repeated treatment.
Arthritis Rheum 2008;58:1566-75.
9. Pers JO, Daridon C, Bendaoud B et al. B-
cell depletion and repopulation in autoim-
mune diseases. Clinic Rev Allergy
Immunol 2008;34:50-5.
10 Anolik JH, Barnard J, Owen T et al.
Delayed memory B cell recovery in periph-
eral blood and lymphoid tissue in systemic
lupus erythematosus after B cell depletion
therapy. Arthritis Rheum 2007;56:3044-56. 
11 Abulayha AM, Tabal SA, Shawesh EI et al.
Depletion of peripheral blood B cells with
rituximab and phenotype characterization
of the recovering population in a patient
with follicular lymphoma. Leuk Res
2010;34:307-11.
12 Anolik JH, Friedberg JW, Zheng B et al. B
cell reconstitution after rituximab treat-
ment of lymphoma recapitulates B cell
ontogeny. Clin Immun 2007;122:139-145.
13 Cooper N, Davies EG, Thrasher AJ.
Repeated courses of rituximab for autoim-
mune cytopenias may precipitate profound
hypogammaglobulinaemia requiring
replacement intravenous immunoglobu-
lin. B J Haematol 2009;146:113-24.
14 Kraan J, Gratama JW, Keeney M,
D'Hautcourt JL. Setting up and calibration
of a flow cytometer for multicolor
immunophenotyping. J Biol Regul
Homeost Agents 2003;17:223-33
15 Hendriksen CF, van der Gun JW,
Kreeftenberg JG. Combined estimation of
tetanus and diphtheria antitoxin in
human sera by the in vitro Toxin-Binding
Inhibition (ToBI) test. J Biol Stand
1989;17:191-200. 
16 De Melker HE, Berbers GA, Nagelkerke NJ
et al. Diphtheria antitoxin levels in the
Netherlands: a population-based study.
Emerg Infect Dis 1999;5:694-700.
17 Kamei K, Ito S, Nozu K et al. Single dose of
rituximab for refractory steroid dependent
nephrotic syndrome in children. Pediatr
Nephrol 2009;24:1321-8.
18 Zarkhin V, Li L, Kambham N, et al. A ran-
domized prospective trial of rituximab for
acute rejection in pediatric renal transplan-
tation. Am J Transplant 2008;8:2607-17.
Brief Report
Figure 2. B-lymphocyte subpopulations. Timeline starts in August 2005, directly after
first rituximab treatment, shows depletion after 2nd rituximab treatment and continues
until roughly 2.5 years remission. Total B-lymphocytes (CD19+) bold line; naive B-lym-
phocytes (CD19+IgD+CD27-) narrow line. Switched memory B-lymphocytes
(CD19+IgD-CD27+) score-dot-dot; non-switched memory B-lymphocytes
(CD19+IgD+CD27+) interrupted line; CD5+ B-lymphocytes dotted line. Reference values
determined in healthy children in our laboratory are shown as vertical lines.
Figure 1. Time schedule of patient’s history. Dotted line: hemoglobin (mmol/L).
Prednisone (mg/kg/day) uninterrupted line; prednisone (mg/kg every other day) inter-
rupted line. Arrows: *rituximab treatment; ** blood sample (resp t = 0, 8, 14, 21, 56, 110,
202, 321, 383, 396, 403, 410, 418, 446, 530, 614, 718, 817, 1085 days after the first rit-
uximab dose); # vaccination. a: first presentation with autoimmune hemolytic anemia
(August 2004); b: first treatment with rituximab (August 2005); c: recovery of B-lympho-
cytes (day 110 after first rituximab treatment); d: relapse and second treatment with rit-
uximab (July 2006); e: recovery of B-lymphocytes (day 218 after 2nd rituximab treat-
ment). Timeline stops in July 2007 when steroids are stopped.
